1.60
-0.07(-4.19%)
Currency In USD
| Previous Close | 1.67 |
| Open | 1.65 |
| Day High | 1.68 |
| Day Low | 1.58 |
| 52-Week High | 4.18 |
| 52-Week Low | 0.6 |
| Volume | 519,706 |
| Average Volume | 660,450 |
| Market Cap | 73.16M |
| PE | -0.98 |
| EPS | -1.64 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 1.27 |
| Change | -0.07 |
If you invested $1000 in Werewolf Therapeutics, Inc. (HOWL) since IPO date, it would be worth $99.38 as of October 19, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Werewolf Therapeutics, Inc. (HOWL) shares 3 years ago, it would be worth $418.85 as of October 19, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
GlobeNewswire Inc.
Oct 08, 2025 12:00 PM GMT
Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Oct 03, 2025 1:00 PM GMT
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to s
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to